Cystic Fibrosis

HomePatientsLung Disease Week at the ATS2016 ▶ Cystic Fibrosis
Cystic Fibrosis Week

Cystic Fibrosis Week

Welcome Message

Although cystic fibrosis (CF) is the most common life-shortening disease in Caucasians, it affects people of many different ethnic backgrounds.  Thirty thousand people in the U.S. and 70,000 people worldwide have CF.  While the majority of morbidity and mortality of CF is due to the lung disease, CF affects many other organs including the sinuses, liver, pancreas, intestines, sweat glands, bones, and reproductive organs. The median survival in CF has increased from 28 years in the early 1990s to approximately 40 years in 2014.  This improvement in survival is due to advances in research with respect to knowledge about underlying disease processes and the development of improved therapeutics.  Despite this remarkable improvement in survival over the past 25 years, further advances are necessary to change CF from a disease that people die from to a disease that people live with.

The American Thoracic Society (ATS) has worked with the Cystic Fibrosis Foundation to improve the lives of people with CF.  The ATS is committed to the CF community and to fighting this disease.  The ATS has promoted awareness of CF and augmented the advocacy work done by the Cystic Fibrosis Foundation.  At the ATS International Conference, groundbreaking results of basic science research and clinical trials in CF are presented each spring.  ATS journals help to disseminate knowledge about CF by serving as a publication outlet for CF research.  The ATS also funds grants to individual investigators who study CF.  In these days of difficult federal funding opportunities, the impact of this cannot be minimized.  That CF is highlighted in a Lung Disease Week at the ATS only confirms this commitment.  The hope is that spotlighting the advances made in CF in the laboratory and in the clinic will help to increase awareness about CF in the general population and to build enthusiasm to further support research funding for CF that will eventually relegate this disease to the medical history books.


Beth Sufian, JD

Beth Sufian, JD
Director, CF Legal Information Hotline
Cystic Fibrosis Foundation
Member, ATS Public Advisory Roundtable

James F. Chmiel, M.D., M.P.H.

James F. Chmiel, M.D., M.P.H.
Director and Chief Executive
Ohio Clinical Trials Collaborative
Professor of Pediatrics
Case Western Reserve University School of Medicine
Board of Director, American Thoracic Society